Retrospective Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 28, 2022; 28(28): 3666-3681
Published online Jul 28, 2022. doi: 10.3748/wjg.v28.i28.3666
How has the disease course of pediatric ulcerative colitis changed throughout the biologics era? A comparison with the IBSEN study
Yiyoung Kwon, Eun Sil Kim, Yon Ho Choe, Mi Jin Kim
Yiyoung Kwon, Yon Ho Choe, Mi Jin Kim, Department of Pediatrics, Samsung Medical Center, Seoul 06351, South Korea
Eun Sil Kim, Department of Pediatrics, Kangbuk Samsung Medical Center, Seoul 03181, South Korea
Author contributions: Kwon Y designed and performed the research and wrote the paper; Kim MJ designed the research and supervised the report; Kim ES and Choe YH designed the research and contributed to the analysis.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of the Samsung Medical Center (IRB File No. SMC 2020-12-005).
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: The authors have no conflict of interests to declare.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Mi Jin Kim, MD, PhD, Associate Professor, Department of Pediatrics, Samsung Medical Center, Ilwon-ro 81, Gangnam-gu, Seoul 06351, South
Received: September 28, 2021
Peer-review started: September 28, 2021
First decision: November 18, 2021
Revised: November 21, 2021
Accepted: June 30, 2022
Article in press: June 30, 2022
Published online: July 28, 2022
Core Tip

Core Tip: This was a retrospective study that assessed how the introduction of biological agents has altered the disease course over time in pediatric ulcerative colitis (UC). Endoscopic remission, relapse rate, steroid-free period, and the quality of life of each group were evaluated as outcomes. Clinical course was plotted with the pediatric UC activity index score, and compared to that of the IBSEN study. The incidence of relapse has decreased and the steroid-free period has increased after the introduction of biological agents. The clinical course also showed a different pattern from the IBSEN study.